Beijing Biotech

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests a new treatment using specially engineered natural killer (NK) cells to attack advanced lung cancer that has spread. About 60 adults whose tumors have certain markers will receive chemotherapy followed by an infusion of these cells. The goal is to find a safe dos…

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This study tests a new treatment for adults with advanced head and neck cancer that has spread or come back. The treatment uses donor immune cells that are engineered to target two cancer markers, EGFR and HER2. Participants first receive chemotherapy to prepare their body, then …

This early-stage trial tests a new treatment for advanced esophageal cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that are designed to recognize and attack cancer cells carrying tw…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…

This study tests whether specially engineered immune cells (CAR-NK cells) can safely treat people with advanced thymus cancers that have not responded to other treatments. Participants will receive cells that target one of three proteins found on their tumor. The goal is to find …

This early-stage trial tests a new type of immune cell therapy (CAR-NK cells) in people with advanced colorectal cancer that has not responded to standard treatments. The cells are designed to target two cancer-related proteins at once, based on each patient's tumor markers. The …

This study tests a new treatment called EB-NK-301, which uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 found on many solid tumors. The trial enrolls 60 adults with advanced or metastatic cancers that have not responded to standard treatmen…

This early-stage trial tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially designed natural killer (NK) cells that target two markers on cancer cells. After a short course of…

This early-phase trial tests a new treatment for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment uses a patient's own immune cells (NK cells) that have been engineered in a lab to better recognize and attack tumor cells. The cells are delivered dire…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins found on stomach cancer cells. The therapy is given to adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. Th…

This early-phase trial tests a one-time infusion of specially engineered immune cells (CAR-NK cells) that target two proteins, CD70 and CAIX, found on kidney cancer cells. The study includes 36 adults with advanced clear cell renal cell carcinoma that has worsened after standard …

This study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This early-phase trial tests a new treatment for people with mesothelioma that cannot be removed by surgery or has come back after standard therapy. The treatment uses donor immune cells (natural killer cells) that are engineered in a lab to recognize and attack two proteins foun…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to s…

This study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on t…

This study tests a new treatment for adults with advanced liver cancer that cannot be removed by surgery or has spread. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins found on liver cancer cells. Participa…

This early-stage study tests a new treatment for people with advanced bladder cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins on cancer cells. Participan…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their t…

This early-stage trial tests a new type of immunotherapy for people with advanced pancreatic cancer that has spread or cannot be removed. The treatment uses specially engineered natural killer (NK) cells that target two cancer-related proteins at once. Up to 42 participants will …

This study tests a new treatment called CAR-NK cells, which are immune cells engineered to recognize and attack cancer. The trial enrolls 60 adults with small cell lung cancer that has come back or not responded to standard treatments. Participants receive the cells along with ch…

This study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells…

This early-stage trial tests a new approach for people with recurrent glioblastoma, a fast-growing brain tumor. Doctors take immune cells called NK cells, engineer them to recognize and attack tumor cells, and deliver them directly into the brain. The study will check safety and …

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses specially engineered natural killer (NK) immune cells that target two cancer-related proteins on tumor cells. Participants receive…

This study tests a new treatment made from donated cord blood cells that are engineered to recognize and attack colorectal cancer cells. It is for people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The trial will check safety and e…